Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | ADH4 | P08319 | 1/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621467 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL58362 | 1.00 | — | — | |
| SCHEMBL149027 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL11109100 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10873634 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL146003 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL76962 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL148471 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10874788 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 | |
| SCHEMBL9661841 | 1.00 | EPHX1 (0.48) | EPHX1ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8093422-B2 | Method for deuteration of an aromatic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-7517990-B2 | Method for deuteration of a heterocyclic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| EP-1707548-A1 | METHOD OF DEUTERATION USING MIXED CATALYST | Wako Pure Chemical Industries, Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20060116535-A1 | Method of deuteration | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20060025596-A1 | Method for deuteration or tritiation of heterocyclic ring | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1577280-A1 | METHOD OF DEUTERIZATION | Wako Pure Chemical Industries, Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-5138067-A | PAF antagonists, antithrombotic, antivasoconstricting, antibronchoconstricting or antitumor agents | SHIONOGI & CO. LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-5047540-A | Platelet Activating Factor Antagonists and Antitumor Agents | SHIONOGI & CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0321296-A1 | Lipid derivatives their preparation and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| US-4504472-A | MICROBIOCIDES, IMMUNOSTIMULANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025596-A1 | Method for deuteration or tritiation of heterocyclic ring | HRH2, HRH4, HDHD5 | EPHX1 1259/4885ADH1B 272/4885ADH1C 715/4885 |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | EPHX1 2426/4885ADH1B 502/4885ADH1C 1044/4885 |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | HRH3, HRH4, AHR | EPHX1 2302/4885ADH1B 501/4885ADH1C 1127/4885 |
| US-20060116535-A1 | Method of deuteration | ARL1, IDH2, IDH3A | EPHX1 2129/4885ADH1B 477/4885ADH1C 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.